Molecular classification of brain tumors guides individualized treatment

doi:10.3969/j.issn.1006-7795.2015.05.026

Journal of Capital Medical University ›› 2015, Vol. 36 ›› Issue (5): 794-799.doi: 10.3969/j.issn.1006-7795.2015.05.026

Previous Articles Next Articles

Molecular classification of brain tumors guides individualized treatment

Gao Hua¹, Zhao Peng², Zhang Yazhuo¹

1. Cell biology, Beijing Neurosurgical Institute, Capital Medical University, Key Laboratory of Central Nervous System Injury, Beijing 100050, China;
2. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

Received:2015-07-14 Online:2015-10-21 Published:2015-10-20
Contact: 张亚卓 E-mail:zyz2004520@yeah.net
Supported by:
This study was supported by National Natural Science Foundation of China (30971005, 81272522, 81072075).

Abstract

Abstract: Primary brain tumors are among the most lethal of all cancers, largely as a result of their lack of responsiveness to current therapy. Numerous new therapies hold great promise for the treatment of patients with brain cancer, but the main challenge is to determine which treatment is most likely to benefit an individual patient. By reviewing advances of brain tumors,we suggest that a more biological approach to brain tumors classification will provide improved means to type these tumors. Any new classification, however, must be based on clinical significance, and we thus point out the pressing need for better clinical endpoints and outcome measures in the field.

Key words: brain tumor, molecular classification, individualized treatment

CLC Number:

Gao Hua, Zhao Peng, Zhang Yazhuo. Molecular classification of brain tumors guides individualized treatment[J]. Journal of Capital Medical University, 2015, 36(5): 794-799.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.05.026

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I5/794

References

[1] Legler J M, GloecklerRies L A, Smith M A, et al.RESPONSE: re: brain and other central nervous system cancers: recent trends in incidence and mortality [J]. J Natl Cancer Inst, 2000,92(1):77A-78A.
[2] Takeshima H, Sawamura Y, Gilbert M R, et al. Application of advances in molecular biology to the treatment of brain tumors[J].Curr Oncol Rep, 2000,2(5):425-433.
[3] Giannini C, Scheithauer B W, Weaver A L, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading[J]. J Neuropathol Exp Neurol, 2001, 60(3):248-262.
[4] Hlaihel C,Boussel L, Cochet H, et al. Dose and image quality comparison between prospectively gated axial and retrospectively gated helical coronary CT angiography[J]. Br J Radiol, 2011, 84(997): 51-57.
[5] Louis D N, Ohgaki H, Wiestler O D, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109.
[6] Phillips H S, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis[J]. Cancer Cell, 2006, 9(3):157-173.
[7] Nutt C L, Mani D R, Betensky R A, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification[J]. Cancer Res, 2003, 63(7):1602-1607.
[8] Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic?[J]. Clin Cancer Res, 2011, 17(13):4588-4599.
[9] Masui K, Cloughesy T F, Mischel P S. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies[J]. Neuropathol Appl Neurobiol, 2012, 38(3):271-291.
[10] Weller M, Pfister S M, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon[J]. Lancet Oncol, 2013, 14(9):e370-e379.
[11] Al-Hajj M, Becker M W, Wicha M, et al. Therapeutic implications of cancer stem cells[J]. Curr Opin Genet Dev, 2004, 14(1):43-47.
[12] Stiles C D, Rowitch D H. Glioma stem cells: a midterm exam[J]. Neuron, 2008, 58(6):832-846.
[13] Sukhdeo K, Hambardzumyan D, Rich J N. Glioma development: where did it all go wrong?[J]. Cell, 2011, 146(2):187-188.
[14] Trouillas J. In search of a prognostic classification of endocrine pituitary tumors[J]. Endocr Pathol, 2014, 25(2):124-132.
[15] Li Z B, Niu G, Wang H, et al. Imaging of urokinase-type plasminogen activator receptor expression using a Cu-64-labeled linear peptide antagonist by microPET[J]. Clin Cancer Res, 2008, 14(15):4758-4766.
[16] Arakaki P A, Marques M R, Santos M C. MMP-1 polymorphism and its relationship to pathological processes[J]. J Biosci, 2009, 34(2):313-320.
[17] Alta M, Bayrak O F, Ayan E, et al.The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma [J].Acta Neurochir (Wien). 2010;152(9):1611-1617.
[18] Hussaini I M, Trotter C, Zhao Y, et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line[J]. Am J Pathol, 2007, 170(1):356-365.
[19] Mete O, Ezzat S, Asa S L. Biomarkers of aggressive pituitary adenomas[J]. J Mol Endocrinol, 2012, 49(2):R69-R78.
[20] Tong Y, Zheng Y, Zhou J, et al. Genomic characterization of human and rat prolactinomas[J]. Endocrinology, 2012, 153(8):3679-3691.
[21] Wang F, Gao H, Li C, et al. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas[J]. J Neurooncol, 2014, 116(1):83-88.
[22] David A, Hwa V, Metherell L A, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity[J]. Endocr Rev, 2011, 32(4):472-497.
[23] Zhan X, Desiderio D M. Signaling pathway networks mined from human pituitary adenoma proteomics data[J]. BMC Med Genomics, 2010, 3:13.
[24] Jiang Z, Gui S, Zhang Y. Analysis of differential gene expression using fiber-optic bead array and pathway analyses in pituitary adenomas[J]. J Clin Neurosci, 2011, 18(10):1386-1391.
[25] Ozfirat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas[J]. Mol Cell Endocrinol, 2010, 326(1-2):71-79.

Molecular classification of brain tumors guides individualized treatment

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei. Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer [J]. Journal of Capital Medical University, 2019, 40(2): 191-194.
[2]	Zhang Chuanbao, Jiang Tao. The Second Grade National Prize for Science and Technology Progress——the innovation and application of key technologies in the diagnosis and treatment of brain glioma [J]. Journal of Capital Medical University, 2018, 39(1): 1-5.
[3]	Yu Chunshui;Li Kuncheng;Qin Wen. A Study of Diffusion Tensor Tractography in Patients with Brain Tumors [J]. Journal of Capital Medical University, 2005, 26(4): 413-417.
[4]	Qi Huimin. Research on Changes in Urinary EGF after Craniocerebral Operations [J]. Journal of Capital Medical University, 1997, 18(3): 242-245.
[5]	Chen Dongling. Chromosome Preparation of Human Brain Tumor by Monolayer Cell Cultures——Preliminary Karyological Analysis of Ten Brain Tumors [J]. Journal of Capital Medical University, 1987, 8(1): 45-50.